A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
PHASE2
A study to evaluate the efficacy and safety of triplet combination of inavo...
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
PHASE3
The purpose of this study is to find out whether a new drug, Ipatasertib, c...
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
PHASE3
This study was a multi-center, randomized, double-blind, placebo controlled...
Status
Completed
Location
University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2)
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
PHASE3
The purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and...